Filtered By:
Drug: Remicade
Management: Medicaid
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study
Conclusions
In the USA, the rate of non-viral OI was higher among new users of TNFI with autoimmune diseases compared to non-biological DMARD users.
Source: Annals of the Rheumatic Diseases - October 5, 2014 Category: Rheumatology Authors: Baddley, J. W., Winthrop, K. L., Chen, L., Liu, L., Grijalva, C. G., Delzell, E., Beukelman, T., Patkar, N. M., Xie, F., Saag, K. G., Herrinton, L. J., Solomon, D. H., Lewis, J. D., Curtis, J. R. Tags: Inflammatory bowel disease, Immunology (including allergy), Bone and joint infections, Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Ca Source Type: research
